rolipram has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Li, Y | 1 |
| Zhu, JY | 1 |
| Fang, D | 1 |
| Ding, HF | 1 |
| Dong, Z | 1 |
| Jing, Q | 1 |
| Su, SB | 1 |
| Huang, S | 1 |
1 other study available for rolipram and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.
Topics: Animals; Cell Line, Tumor; Colforsin; Computational Biology; Cyclic AMP; Cyclic Nucleotide Phosphodi | 2016 |